Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Jan;49(1):333-41.
doi: 10.1167/iovs.07-0214.

Effect of eye pigmentation on transscleral drug delivery

Affiliations
Comparative Study

Effect of eye pigmentation on transscleral drug delivery

Narayan P S Cheruvu et al. Invest Ophthalmol Vis Sci. 2008 Jan.

Abstract

Purpose: To determine the influence of eye pigmentation on transscleral retinal delivery of celecoxib.

Methods: Melanin content in ocular tissues of both the strains was determined by sodium hydroxide solubilization

Method: The affinity of celecoxib to synthetic and natural melanin was estimated by co-incubating celecoxib and melanin in isotonic phosphate-buffered saline. The binding affinity (k) and the maximum binding (r(max)) for celecoxib to both natural and synthetic melanin were estimated. Suspension of celecoxib (3 mg/rat) was injected periocularly into one eye of Sprague-Dawley (SD, albino) and Brown Norway (BN, pigmented) rats. The animals were euthanatized at the end of 0.25, 0.5, 1, 2, 3, 4, 8, or 12 hours after the drug was administered, and celecoxib levels in ocular tissues (sclera, choroid-RPE, retina, vitreous, lens, and cornea) were estimated with an HPLC assay. In addition, celecoxib-poly(lactide) microparticles (750 microg drug/rat) were administered periocularly in SD and BN rats, and celecoxib levels in these eye tissues were assessed on day 8, to determine the effectiveness of the sustained release system.

Results: The r(max) and k for celecoxib's binding to natural melanin were (3.92 +/- 0.06) x 10(-7) moles/mg of melanin and (0.08 +/- 0.01) x 10(6) M(-1), respectively. The affinity and the extent of celecoxib's binding to natural melanin were not significantly different from those observed with synthetic melanin. The concentrations of melanin in choroid-RPE, sclera, and retina of BN rats were 200 +/- 30, 12 +/- 4, and 3 +/- 0.2 mug/mg tissue, respectively. Melanin was not detectable in the vitreous, lens, and cornea of BN rats. In SD rats, melanin was not detected in all tissues assessed except in the choroid-RPE, wherein melanin-like activity was 100-fold less than in BN rats. The area under the curve (AUC) for tissue concentration versus time profiles for animals administered with celecoxib suspension was not significantly different between the two strains for sclera, cornea, and lens. However, the retinal (P = 0.001) and vitreal (P = 0.001) AUCs of celecoxib in the treated eyes were approximately 1.5-fold higher in SD rats than in BN rats. Further, the choroid-RPE AUC in the treated and untreated eyes, respectively, were 1.5-fold (P = 0.001) and 2-fold (P = 0.0001) higher in BN rats than in SD rats. With celecoxib-poly(lactide) microparticles, choroid-RPE, retina, and vitreous concentrations on day 8 exhibited similar trends in differences between the two strains, with the differences being greater than those recorded for the celecoxib suspension.

Conclusions: Transscleral retinal and vitreal drug delivery of lipophilic celecoxib is significantly lower in pigmented rats than in albino rats. This difference may be attributable to significant binding of celecoxib to melanin and its accumulation/retention in the melanin-rich choroid-RPE of pigmented rats. The hindrance of retinal and vitreal drug delivery by the choroid-RPE in pigmented rats is also true of sustained-release microparticle systems.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ocular melanin concentration in SD (□) and BN (■) rats. No melanin or melanin-like activity was detected in cornea, lens, and vitreous in both the species and in sclera and retina as well in SD rats. *Significantly different from SD rats. Significantly different from the †choroid-RPE and ‡scleral melanin concentration. Data are presented as the mean ± SD for n = 4. *P = 0.0001; †,‡P = 0.001.
Figure 2
Figure 2
Ocular tissue concentrations of celecoxib after subconjunctival injection in SD (△) and BN (●) rats. Solid line: ipsilateral eye; dashed line: contralateral eye. Data are presented as the mean ± SD (n = 4).
Figure 3
Figure 3
Celecoxib availability (AUC0-∞) to the ocular tissues (μg · h/g tissue) after subconjunctival injection (3 mg to one eye) in albino (SD) and pigmented (BN) rats. Data are presented as the mean ± SD for n = 4. *P = 0.04, †P = 0.001, and ‡P = 0.0001, when compared with corresponding BN rat tissue.
Figure 4
Figure 4
In vitro release of celecoxib from poly(lactide) microparticles. Celecoxib particles equivalent to 20 μg of celecoxib were suspended in a dialysis bag and immersed in 50 mL of PBS. Cumulative percentage release of celecoxib is plotted. Data are presented as the mean ± SD for n = 3.
Figure 5
Figure 5
Ocular tissue concentrations of celecoxib at the end of 8 days in albino (SD) and pigmented (BN) rats after periocular injection of celecoxib-PLA microparticles. Data are presented as the mean ± SD for n = 4. *P = 0.0001 compared with the corresponding BN rat tissue.
Figure 6
Figure 6
Ratio of ocular tissue AUCs (for celecoxib suspension) or tissue concentrations (for celecoxib-PLA particles) between pigmented (BN) and albino (SD) rats. Data are presented as the ratio of the mean AUCs or concentrations for n = 4. In the celecoxib-PLA microparticle group, drug levels were not detected in the contralateral sclera, lens, and cornea in albino SD rats and in the contralateral lens and cornea of BN rats. Therefore, the BN-to-SD rat tissue ratio was not provided for these contralateral tissues.

Similar articles

Cited by

References

    1. Marra M, Gukasyan HJ, Raghava S, Kompella UB. 2nd Ophthalmic Drug Development and Delivery Summit San Diego, CA, 19–20 September 2006. Expert Opin Drug Deliv. 2007;4:77–85. - PubMed
    1. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv. 2004;1:99–114. - PMC - PubMed
    1. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol. 2002;47:S41–S52. - PubMed
    1. Ambati J, Adamis AP. Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res. 2002;21:145–151. - PubMed
    1. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev. 2001;52:37–48. - PubMed

Publication types

MeSH terms